You are here

  • Home
  • Archive
  • Volume 80, Issue 2
  • Response to ‘Is there a future for hydroxychloroquine/chloroquine in prevention of SARS-CoV-2 infection (COVID-19)?’ by Moiseev et al

Article Text

Article menu
Download PDFPDF
Correspondence response
Response to ‘Is there a future for hydroxychloroquine/chloroquine in prevention of SARS-CoV-2 infection (COVID-19)?’ by Moiseev et al
  1. Francesca Romana Spinelli,
  2. Fulvia Ceccarelli,
  3. Manuela Di Franco,
  4. Fabrizio Conti
  1. Dipartimento di Scienze Cliniche, Internistiche, Anestesiologiche e Cardiovascolari-Reumatologia, Sapienza University of Rome, Roma, Italy
  1. Correspondence to Dr Francesca Romana Spinelli, Dipartimento di Scienze Cliniche, Internistiche, Anestesiologiche e Cardiovascolari-Reumatologia, Sapienza University of Rome, Roma 00161, Italy; francescaromana.spinelli{at}uniroma1.it

https://doi.org/10.1136/annrheumdis-2020-217636

Statistics from Altmetric.com

    We thank Sergei Moiseev and colleagues for their comment in response to our letter ‘To consider or not antimalarials as a prophylactic intervention in the SARS-CoV-2 (Covid-19) pandemic’.1 2

    Antimalarial drugs hydroxychloroquine (HCQ) and chloroquine have been largely used for treating patients with systemic lupus erythematosus and other autoimmune rheumatic diseases (ARDs) for decades, and they are safe and well tolerated in such patients.3 Conversely, there is still little evidence on their effectiveness in patients with Covid-19. As Moiseev and colleagues have pointed out, more data have been published after the submission of our letter; therefore, we welcome the opportunity to give an update. The results of five studies are now available: three open-label and two randomised controlled trials4–8 (table 1). All studies have small sample sizes and enrolled non-critically ill patients. Gautret et al extended their previous results confirming the fast reduction of viral load in 80 hospitalised Covid-19 patients treated …

    View Full Text

    Footnotes

    • Handling editor Josef S Smolen

    • Contributors FRS and FCo wrote the response letter. FC and MDF approved the manuscript.

    • Funding The authors have not declared a specific grant for this research from any funding agency in the public, commercial or not-for-profit sectors.

    • Competing interests None declared.

    • Patient and public involvement Patients and/or the public were not involved in the design, or conduct, or reporting, or dissemination plans of this research.

    • Patient consent for publication Not required.

    • Provenance and peer review Commissioned; internally peer reviewed.

    Linked Articles